The further education of pastoral ministers should include dealing with dementia says Bishop Franz-Josef Bode, deputy president of the German bishops' conference, speaking about a condition that is growing rapidly worldwide.
1. In this randomized controlled trial, over a period of 240 weeks, solanezumab did not slow cognitive decline as compared to placebo in patients with preclinical Alzheimer’s disease. 2. Solanezumab did not change the levels of amyloid levels in the brain as compared to placebo in persons with preclinical Alzheimer’s disease. Evidence Rating Level: 1 (Excellent)